Premium
LYMRIT 37‐01: UPDATED RESULTS OF A PHASE I/II STUDY OF 177 LU‐LILOTOMAB SATETRAXETAN, A NOVEL CD37‐TARGETED ANTIBODY‐ RADIONUCLIDE‐CONJUGATE IN RELAPSED NHL PATIENTS
Author(s) -
Kolstad A.,
Madsbu U.,
Beasley M.,
Bayne M.,
Illidge T.,
O'Rourke N.,
Lagerlöf I.,
Hájek R.,
Jurczak W.,
Willenbacher E.,
Blakkisrud J.,
Muftuler Løndalen A.,
Rojkjaer L.,
Baylor Curtis L.,
Bloma M.,
Turner S.,
Bolstad N.,
Spetalen S.,
Erlanson M.,
Nygaard S.,
Holte H.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_142
Subject(s) - medicine , radioimmunotherapy , follicular lymphoma , rituximab , mantle cell lymphoma , nuclear medicine , regimen , gastroenterology , surgery , oncology , lymphoma , antibody , monoclonal antibody , immunology